Nanoparticle Treatment Shrinks Breast Cancer Tumors
Researchers developed hybrid nanoparticles that successfully deliver p53 mRNA to reduce tumor volume in mouse models.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Do you support prioritizing new nanoparticle technology to improve the delivery of cancer treatments?
Scientists have created hybrid strontium sulfite lipid nanoparticles designed to restore p53 protein function in breast cancer cells. This new delivery method demonstrated a 76% reduction in average tumor volume compared to untreated controls in mouse models.
Why it matters
Restoring p53 protein function is a critical goal in cancer research, as mutations in this gene often disable the body's natural tumor-suppression capabilities. This hybrid approach aims to overcome existing hurdles in therapeutic mRNA delivery for oncology applications.
The hybrid carrier achieved a 70% binding efficiency for nucleic acids, with luciferase assays indicating threefold higher gene expression in MCF-7 cells. Treated mice showed an average tumor volume of 260 mm3 versus 1,100 mm3 for the untreated group.
The players
MCF-7
MCF-7 is a widely used human breast cancer cell line that is essential for studying hormone response and gene expression in oncology research.
The details
The researchers synthesized strontium sulfite nanoparticles and combined them with lipids to form complexes with a 946 nm hydrodynamic diameter. The treatment effectively increased the proportion of apoptotic cells in MCF-7 models, although co-delivery with EGFR-targeting siRNA did not enhance antitumor effects.
Timeline
4 hours after administration for biodistribution assessment.
Day 26 for final measurement of tumor volume in the mouse model.
The Big Picture
This development follows the successful implementation of mRNA delivery platforms used in COVID-19 vaccines to address complex cellular pathologies. It extends the utility of lipid-based nanoparticles into the specialized field of oncological gene therapy.
This development could eventually lead to new, more precise mRNA-based treatment options for patients with difficult-to-treat breast cancers. It currently remains in the preclinical phase, meaning it is not yet available for human clinical use or patient application.
The takeaway
This study highlights the potential of hybrid nanotechnology to improve the delivery of therapeutic genetic materials into tumors. Future efforts will focus on validating whether this platform remains effective and safe in more complex biological environments.
Further reading
Learn more about ongoing breakthroughs in oncological research on our Cancer page.
More information
Read the full details of the scientific study journal article.
Source note: This article includes information reported by AZoNano.
Live Poll
Do you support prioritizing new nanoparticle technology to improve the delivery of cancer treatments?
